DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to Solana (SOL). Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged ...

Explore the new design, including Liquid Glass, which combines the optical properties of glass with a sense of fluidity. Learn more about Liquid Glass and the new design. https://www.youtube.com/watch?v=IrGYUq1mklk #WWDC25 #LiquidGlass ...

Market Overview - The Liquid Waste Management Market was valued at USD 100.64 Billion in 2024 and is projected to reach USD 126.43 Billion by 2030, with a compound annual growth rate (CAGR) of 3.72% [1][14]. Market Drivers - Growth is driven by increased environmental awareness, rapid industrialization, and stringent regulatory mandates across regions [2]. - The intensification of environmental regulations is a significant factor, as governments enforce strict discharge and treatment protocols to control pollution and ensure public health safety [5][6]. - The rising demand for specialized infrastructure and service providers is a result of legal obligations for industries to treat liquid effluents before discharge, particularly in high-risk sectors [5][6]. Market Challenges - High operational and maintenance costs pose a significant challenge for the industry, as advanced treatment solutions require skilled personnel and constant upkeep [8]. - Developing economies face difficulties in affording or maintaining necessary infrastructure due to budget constraints, impacting the adoption of effective treatment solutions [9]. Market Trends - The emergence of decentralized waste management systems is transforming the market, particularly in regions where centralized systems are impractical [10]. - Modular and containerized units, bio-digesters, and small-scale wetland systems are gaining popularity for localized treatment capabilities [11][12]. - Decentralized systems improve treatment coverage in underserved locations, aiding public health and sanitation efforts [12]. Key Market Players - Major companies in the Liquid Waste Management sector include Veolia Environnement S.A., SUEZ SA, Clean Harbors, Inc., Waste Management, Inc., and others [16].

BOCA RATON, FL, June 10, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the "Company" or "DeFi Dev Corp."), the first US public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced a strategic partnership with Exponent, a leading Solana-native yield strategy platform. This collaboration will see dfdvSOL, a liquid staking token (LST) adopted by DeFi Dev Corp., integrated into Exponent's innovative fixed-yield and leverage yield farming vaults. Wit ...

苹果宣布了多年来操作系统最大一次的设计变革。 北京时间6月10日凌晨，苹果公司举办全球开发者大会（WWDC 2025），介绍了苹果在软件和服务方 面的众多革新。 知名科技记者马克·古尔曼认为，WWDC带来不少亮点，包括全新的设计语言、新的操作系统命名方 式，iPhone的电话和相机应用程序更新等。他尤其指出iPad模仿Mac的全新多任务处理系统"令人兴 奋"。 推出全新"液态玻璃"设计 在本次WWDC上，苹果宣布推出新的操作系统设计，这是自2013年以来iOS首次进行重大设计革新。 苹果公司CEO蒂姆·库克（Tim Cook） 新设计扩展到iOS 26、 iPadOS 26、macOS Tahoe 26、 watchOS 26和tvOS 26。 2013年的iOS7彻底抹去了仿真皮革、金属钉扣等拟物元素，用纯色块、纤细字体和层次分明的半透明 图层重构了数字界面逻辑。iOS7定义了此后数年的设计语言。 苹果将这一新外观称为"Liquid Glass（液态玻璃）"。这种半透明质感可反射和折射周围环境，并随内 容动态变化，帮助用户更聚焦于核心内容，为控件、导航栏、应用图标、小组件等元素赋予全新活力。 Liquid ...

毫不夸张的说：这是自 iOS 7 以来，近十二年时间里，iOS 迎来的最重大的一次更新。 在刚刚过去的 WWDC 2025 开幕式上，苹果宣布了其全新的跨系统 UI 设计语言「Liquid Glass」，通过极致的透视和散射，尽最大能力在电子屏幕上模拟 出了极为优秀的真实玻璃质感： 更重要的则是名称的前半段——「Liquid」。玻璃作为固态的物品本身并不会移动，然而液态一词却很好的阐明了本次 iOS 26 与 iPadOS 26 中另一部分非 常直观的改变：极为丰富的动画与动效细节。 爱范儿在苹果 iOS 26 开发者预览版推送后第一时间上手尝试，我们发现： iOS 与 iPadOS 26 中的「液态玻璃」是一种非常拟物化的表达。这与苹果从 iOS 7 开始坚持至今近十二年的扁平化风格有着明显区别，同时也和更早前的 纯粹拟物完全不同。 或许是为了呼应代表苹果下一个世代的产品哲学，总之在 Vision Pro 面世两年后，visionOS 上面那套无时无刻都在与周围环境产生交互的 UI 界面终于完 成了跨越，来到了苹果全部的软件平台上。 iOS 26 的玻璃感从更新完成后进入主界面的一瞬间便扑面而来。除了已经完 ...

- [Joanna] Apple just announced iOS 26, the biggest redesign in years. Can you say. - Liquid glass. - Liquid glass. - Liquid glass.- Which sounds like some sort of new vodka. And no, you didn't miss iOS 19 20, 21, 22, 23, 24, or 25. Apple's now naming these after years, except it's doing the car maker thing and going with the coming year.Let's break down 26 of the biggest features for iOS 26. Just joking, we're doing five. Number one, the redesign.- [Representative] Liquid glass is translucent and behaves j ...

Financial Data and Key Metrics Changes - The company reported record consumables revenue exceeding $18 million, reflecting strong product development efforts and an expanded assay portfolio [5][6] - The Accelerator services business grew by 36% year-on-year, although some pharma projects were pushed to later quarters due to market conditions [7][8] - Overall, the company expects to stabilize and return to a pace of clinical trials and preclinical work as the biopharma market stabilizes [8][10] Business Line Data and Key Metrics Changes - Consumables revenue showed significant growth, driven by the introduction of over 20 new assays last year and a similar cadence expected this year [5][6] - The instruments segment remained stable year-over-year, indicating consistent demand [6] - The Accelerator Lab has become a significant revenue source, contributing approximately 30% of the business and showing strong growth in clinical and market adoption [18][20] Market Data and Key Metrics Changes - The company has about 20-22% exposure to the government end market, with some paralysis in customer decisions due to uncertainties in grant funding [12][13] - The academic research market is experiencing pressure, but the company is finding ways to mitigate this through services and consumables [12][13] Company Strategy and Development Direction - The company aims to expand its addressable market from $1 billion in neurology to $5 billion by including immunology and immuno-oncology [42][43] - The introduction of the SYM-one platform is expected to enhance sensitivity and complexity in immunology and oncology, broadening the company's market reach [30][34] - The company is focused on maintaining R&D investments while implementing cost-saving measures, ensuring continued innovation in key areas [39][40] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are delays in project decisions, there have been no cancellations, indicating a cautious but positive outlook for future projects [9][10] - The company is optimistic about the growth potential in the liquid biopsy market, emphasizing the importance of protein biomarkers alongside DNA [44][46] - Management believes that the adoption of blood-based biomarkers for Alzheimer's will increase as therapy adoption improves, creating a synergistic effect [54][56] Other Important Information - The company is preparing for the launch of the SYM-one platform, which will be compatible with over 20,000 flow cytometers, significantly increasing its market reach [32][36] - The company has initiated a cost savings program targeting $55 million in savings by the end of 2026, focusing on G&A and volume-related costs [38][39] Q&A Session Summary Question: Can you discuss the recent Q1 results and the impact of academic funding concerns? - The company reported strong consumables growth but noted that academic funding concerns have affected the outlook for the Accelerator Lab [4][5] Question: What is the exposure to the government end market and the impact of NIH spending cuts? - Approximately 20-22% of customers have NIH exposure, and while there is some paralysis in decision-making, the company is finding ways to support these customers [12][13] Question: How does the Accelerator Lab contribute to the business? - The Accelerator Lab has evolved into a significant revenue source, providing stability and repeat business, especially in a CapEx constrained environment [18][20] Question: What are the expectations for the SYM-one platform launch? - The SYM-one platform is expected to enhance sensitivity and complexity in immunology and oncology, with a launch planned before the end of the year [30][34] Question: How does the company plan to balance cost savings with R&D investments? - The company is implementing cost savings primarily in G&A and volume-related areas while maintaining strong investments in R&D and innovation [39][40] Question: What is the rationale behind the Akoya acquisition? - The acquisition aims to increase the addressable market and achieve synergies through a unified operating line and commercial team, targeting profitability by 2026 [42][43]

Liquid glass is translucent and behaves just like glass in the real world. Its color is informed by your content and intelligently adapts between light and dark environments. And as a distinct functional layer that sits above your app, the material dynamically morphs when you need more options or as you move between views.We've applied this same dynamic nature across other experiences. Instead of taking over your whole display, alerts appear from where you tap. Context menus expand into an easily scannable ...

Summary of Guardant Health (GH) FY Conference Call - June 09, 2025 Company Overview - **Company**: Guardant Health (GH) - **Industry**: Life Sciences Tools and Diagnostics Key Highlights and Core Points 1. **Strong Business Performance**: The company reported significant growth in the first half of the year, particularly with the G360 therapy selection platform, driven by new features and the smart liquid biopsy platform [3][4] 2. **REVEAL Test Success**: The REVEAL test for colorectal cancer (CRC) surveillance is gaining traction, with increasing volumes and reimbursement developments [4][12] 3. **Breast Cancer Indication**: A second publication in breast cancer was recently released, with plans to submit for Medicare reimbursement [4][10] 4. **Shield Test Updates**: The Shield test has seen a price increase from $9.20 to $14.95, and it has received ADLT status, indicating strong market positioning [4][35] 5. **NCCN Guidelines Impact**: The updated NCCN guidelines recommending testing every three years for Shield are expected to positively impact adoption and coverage [7][8] 6. **Breakthrough Device Designation**: Shield received breakthrough device designation for multi-cancer detection, which may expedite market entry and reimbursement discussions [10][11] 7. **ASCO Conference Insights**: The company presented significant data at ASCO, including the largest MRD study to date, validating the REVEAL test as a decision support tool [12][13] 8. **Competitive Landscape**: Guardant Health maintains a competitive edge with its smart liquid biopsy platform, which offers faster results and higher sensitivity compared to competitors [19][20] 9. **Tissue Test Launch**: The launch of Guardant360 Tissue aims to penetrate the crowded tissue testing market, leveraging the company's established liquid biopsy reputation [24][26] 10. **MRD Test Expansion**: The REVEAL test is gaining traction among patients who are further out from surgery or have inaccessible tissue samples, indicating a strong market opportunity [29][30] 11. **First Mover Advantage**: The company emphasizes the importance of its first mover advantage in the screening market, particularly with the Shield test [33][34] 12. **ASP Growth**: The average selling prices (ASPs) for Guardant360 and REVEAL tests have increased significantly, contributing to revenue growth [39][40] 13. **Path to Profitability**: The company targets breakeven by 2028, with a focus on reducing cash burn and improving gross margins across its product portfolio [47][48] 14. **Long-term Gross Margin Goals**: Guardant Health aims for gross margins of at least 60% across all products, with specific targets for Guardant360 and REVEAL [50][51] Additional Important Insights - **Biopharma Business Success**: The biopharma segment has shown strong growth, with over 80 pharmaceutical companies utilizing Guardant's services [58][59] - **Sales Team Effectiveness**: The company has achieved high effectiveness and perceived utility in its oncology sales team, which is crucial for market penetration [28][62] - **Future Growth Potential**: The company believes that the combination of new product launches, data releases, and market dynamics will drive significant growth in the coming years [64][65]